Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

KUPPER A WINTERGERST

Allopathic & Osteopathic Physicians Pediatrics Pediatric Endocrinology

NPI
1124159009
CMS profile
187525
Location
LOUISVILLE, KY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$140,580.66

93 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

By paying entity

PY2024 · entire year · sorted by reported total

Paying entityAmountRecords
SANOFI-AVENTIS U.S. LLC $140,481.14 92
Tandem Diabetes Care, Inc. $99.52 1

Page 2 of 2; records 51–93 of 93 matching records. This page contains 43 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

KUPPER A WINTERGERST

NPI 1124159009 · CMS profile ID 187525

Allopathic & Osteopathic Physicians / Pediatrics / Pediatric Endocrinology

LOUISVILLE, KY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–93 of 93 matching records. This page contains 43 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1124159009?year=2024&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
KUPPER A WINTERGERST, NPI 1124159009, CMS profile ID 187525. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–93 of 93 matching records. This page contains 43 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1124159009?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). KUPPER A WINTERGERST, NPI 1124159009, CMS profile ID 187525. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–93 of 93 matching records. This page contains 43 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1124159009?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
KUPPER A WINTERGERST, NPI 1124159009, CMS profile ID 187525, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–93 of 93 matching records. This page contains 43 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1124159009?year=2024&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

93 matching records · $140,580.66 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 93 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–93 of 93.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
SANOFI-AVENTIS U.S. LLC $28.5608/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139721352 CMS
SANOFI-AVENTIS U.S. LLC $152.1608/13/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139721354 CMS
SANOFI-AVENTIS U.S. LLC $184.9408/13/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139721370 CMS
SANOFI-AVENTIS U.S. LLC $6,773.0008/13/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139721372 CMS
SANOFI-AVENTIS U.S. LLC $1,229.4306/06/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139721296 CMS
SANOFI-AVENTIS U.S. LLC $562.5706/06/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139721298 CMS
SANOFI-AVENTIS U.S. LLC $8,063.0006/06/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139721300 CMS
SANOFI-AVENTIS U.S. LLC $206.3106/06/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139721308 CMS
SANOFI-AVENTIS U.S. LLC $53.7706/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139721310 CMS
SANOFI-AVENTIS U.S. LLC $121.2006/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139721312 CMS
SANOFI-AVENTIS U.S. LLC $7,095.0005/31/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139721294 CMS
SANOFI-AVENTIS U.S. LLC $555.9805/31/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139721374 CMS
SANOFI-AVENTIS U.S. LLC $324.9005/31/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139721376 CMS
SANOFI-AVENTIS U.S. LLC $29.9305/31/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139721378 CMS
SANOFI-AVENTIS U.S. LLC $59.8705/31/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139721380 CMS
SANOFI-AVENTIS U.S. LLC $29.9305/31/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139721382 CMS
SANOFI-AVENTIS U.S. LLC $172.4505/31/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139721384 CMS
SANOFI-AVENTIS U.S. LLC $42.4505/31/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139721386 CMS
SANOFI-AVENTIS U.S. LLC $33.9205/31/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139721388 CMS
SANOFI-AVENTIS U.S. LLC $6,773.0005/21/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139721330 CMS
SANOFI-AVENTIS U.S. LLC $38.9505/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139721332 CMS
SANOFI-AVENTIS U.S. LLC $170.1805/21/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139721340 CMS
SANOFI-AVENTIS U.S. LLC $5,483.0005/20/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139721302 CMS
SANOFI-AVENTIS U.S. LLC $106.0905/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139721304 CMS
SANOFI-AVENTIS U.S. LLC $97.5505/20/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139721306 CMS
SANOFI-AVENTIS U.S. LLC $34.1105/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139721284 CMS
SANOFI-AVENTIS U.S. LLC $100.2903/07/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139721268 CMS
SANOFI-AVENTIS U.S. LLC $31.8003/07/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139721270 CMS
SANOFI-AVENTIS U.S. LLC $334.9803/07/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139721272 CMS
SANOFI-AVENTIS U.S. LLC $32.0703/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139721274 CMS
SANOFI-AVENTIS U.S. LLC $426.3403/07/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139721276 CMS
SANOFI-AVENTIS U.S. LLC $2,903.0003/07/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139721278 CMS
SANOFI-AVENTIS U.S. LLC $81.2103/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139721280 CMS
SANOFI-AVENTIS U.S. LLC $426.3403/07/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139721334 CMS
SANOFI-AVENTIS U.S. LLC $8,063.0003/07/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139721336 CMS
SANOFI-AVENTIS U.S. LLC $5.5003/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139721338 CMS
SANOFI-AVENTIS U.S. LLC $492.1802/16/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139721314 CMS
SANOFI-AVENTIS U.S. LLC $367.2502/16/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139721316 CMS
SANOFI-AVENTIS U.S. LLC $265.5702/16/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139721318 CMS
SANOFI-AVENTIS U.S. LLC $296.5202/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139721320 CMS
SANOFI-AVENTIS U.S. LLC $33.9202/16/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139721322 CMS
SANOFI-AVENTIS U.S. LLC $17,415.0002/16/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139721324 CMS
Tandem Diabetes Care, Inc. $99.5202/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1138745601 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $252.37 3
PY2022 $775.72 4
PY2023 $17,884.23 34
PY2024 $140,580.66 93
PY2025 $153,561.01 79

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2022, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2022 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $1,618.07 12
PY2025 Principal investigator $17,533.10 9
PY2024 Principal investigator $50,916.49 112
PY2023 Principal investigator $1,129,363.54 231
PY2022 Principal investigator $26,452.01 515
PY2021 Recipient $561.03 3
PY2021 Principal investigator $39,390.32 190
PY2020 Principal investigator $150,699.27 28
PY2019 Principal investigator $74,383.52 26

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

21 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme LLC $449.60 12/31/2025 Non-covered Recipient Entity
University of Louisville Foundation Inc.
A Phase III, Multicenter, Double-Blind, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of Sitagliptin in Pediatric Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control No dispute reported 06/30/2026 1232917937
Principal investigator 1 Dompe Farmaceutici S.p.A. $2,540.20 12/01/2025 Non-covered Recipient Entity
University of Louisville Research Foundation Inc
A phase 2, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of 400 mg twice a day oral ladarixin in patients with new-onset type 1 diabetes and preserved cell function at baseline. NB THIS STUDY TITLE IS THE NEW STUDY TITLE; THE STUDY IS UNDERGOING PROTOCOL AMENDMENT SUBMISSIONS AND HAS CHANGED ITS STUDY PHASE AND STUDY TITLE. No dispute reported 06/30/2026 1248399026
Principal investigator 1 Dompe Farmaceutici S.p.A. $8,432.00 12/01/2025 Non-covered Recipient Entity
University of Louisville Research Foundation Inc
A phase 2, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of 400 mg twice a day oral ladarixin in patients with new-onset type 1 diabetes and preserved cell function at baseline. NB THIS STUDY TITLE IS THE NEW STUDY TITLE; THE STUDY IS UNDERGOING PROTOCOL AMENDMENT SUBMISSIONS AND HAS CHANGED ITS STUDY PHASE AND STUDY TITLE. No dispute reported 06/30/2026 1248399032
Principal investigator 1 Novo Nordisk AS $1,600.00 10/29/2025 Non-covered Recipient Entity
UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION
NN9924-4437 No dispute reported 06/30/2026 1213723213
Recipient SANOFI US SERVICES INC. $117.72 07/11/2025 Covered Recipient Physician A randomized, double-blind, 2-arm, Phase 3 study to investigate efficacy and safety of teplizumab compared with placebo in participants 1 to 25 years of age with newly diagnosed Stage 3 Type 1 Diabetes (T1D) No dispute reported 06/30/2026 1226120487
Recipient SANOFI US SERVICES INC. $70.00 07/11/2025 Covered Recipient Physician A randomized, double-blind, 2-arm, Phase 3 study to investigate efficacy and safety of teplizumab compared with placebo in participants 1 to 25 years of age with newly diagnosed Stage 3 Type 1 Diabetes (T1D) No dispute reported 06/30/2026 1226120509
Recipient SANOFI US SERVICES INC. $14.42 07/11/2025 Covered Recipient Physician A randomized, double-blind, 2-arm, Phase 3 study to investigate efficacy and safety of teplizumab compared with placebo in participants 1 to 25 years of age with newly diagnosed Stage 3 Type 1 Diabetes (T1D) No dispute reported 06/30/2026 1226120514
Principal investigator 1 Novo Nordisk AS $728.00 06/23/2025 Non-covered Recipient Entity
UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION
NN9924-4437 No dispute reported 06/30/2026 1213714212
Recipient SANOFI US SERVICES INC. $85.00 06/19/2025 Covered Recipient Physician A randomized, double-blind, 2-arm, Phase 3 study to investigate efficacy and safety of teplizumab compared with placebo in participants 1 to 25 years of age with newly diagnosed Stage 3 Type 1 Diabetes (T1D) No dispute reported 06/30/2026 1226120496
Recipient SANOFI US SERVICES INC. $79.61 06/19/2025 Covered Recipient Physician A randomized, double-blind, 2-arm, Phase 3 study to investigate efficacy and safety of teplizumab compared with placebo in participants 1 to 25 years of age with newly diagnosed Stage 3 Type 1 Diabetes (T1D) No dispute reported 06/30/2026 1226120501
Recipient SANOFI US SERVICES INC. $75.00 06/19/2025 Covered Recipient Physician A randomized, double-blind, 2-arm, Phase 3 study to investigate efficacy and safety of teplizumab compared with placebo in participants 1 to 25 years of age with newly diagnosed Stage 3 Type 1 Diabetes (T1D) No dispute reported 06/30/2026 1226120505
Recipient SANOFI US SERVICES INC. $374.47 06/19/2025 Covered Recipient Physician A randomized, double-blind, 2-arm, Phase 3 study to investigate efficacy and safety of teplizumab compared with placebo in participants 1 to 25 years of age with newly diagnosed Stage 3 Type 1 Diabetes (T1D) No dispute reported 06/30/2026 1226120527
Recipient SANOFI US SERVICES INC. $357.23 06/19/2025 Covered Recipient Physician A randomized, double-blind, 2-arm, Phase 3 study to investigate efficacy and safety of teplizumab compared with placebo in participants 1 to 25 years of age with newly diagnosed Stage 3 Type 1 Diabetes (T1D) No dispute reported 06/30/2026 1226120530
Recipient SANOFI US SERVICES INC. $153.48 06/19/2025 Covered Recipient Physician A randomized, double-blind, 2-arm, Phase 3 study to investigate efficacy and safety of teplizumab compared with placebo in participants 1 to 25 years of age with newly diagnosed Stage 3 Type 1 Diabetes (T1D) No dispute reported 06/30/2026 1226120541
Recipient SANOFI US SERVICES INC. $85.00 06/18/2025 Covered Recipient Physician A randomized, double-blind, 2-arm, Phase 3 study to investigate efficacy and safety of teplizumab compared with placebo in participants 1 to 25 years of age with newly diagnosed Stage 3 Type 1 Diabetes (T1D) No dispute reported 06/30/2026 1226120492
Recipient SANOFI US SERVICES INC. $4.88 06/18/2025 Covered Recipient Physician A randomized, double-blind, 2-arm, Phase 3 study to investigate efficacy and safety of teplizumab compared with placebo in participants 1 to 25 years of age with newly diagnosed Stage 3 Type 1 Diabetes (T1D) No dispute reported 06/30/2026 1226120519
Recipient SANOFI US SERVICES INC. $201.26 06/18/2025 Covered Recipient Physician A randomized, double-blind, 2-arm, Phase 3 study to investigate efficacy and safety of teplizumab compared with placebo in participants 1 to 25 years of age with newly diagnosed Stage 3 Type 1 Diabetes (T1D) No dispute reported 06/30/2026 1226120534
Principal investigator 1 Novo Nordisk AS $994.00 05/21/2025 Non-covered Recipient Entity
UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION
NN9924-4437 No dispute reported 06/30/2026 1213712862
Principal investigator 1 Dompe Farmaceutici S.p.A. $1,030.00 05/19/2025 Non-covered Recipient Entity
University of Louisville Research Foundation Inc
A phase 2, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of 400 mg twice a day oral ladarixin in patients with new-onset type 1 diabetes and preserved cell function at baseline. NB THIS STUDY TITLE IS THE NEW STUDY TITLE; THE STUDY IS UNDERGOING PROTOCOL AMENDMENT SUBMISSIONS AND HAS CHANGED ITS STUDY PHASE AND STUDY TITLE. No dispute reported 06/30/2026 1248399024
Principal investigator 1 Dompe Farmaceutici S.p.A. $729.30 02/18/2025 Non-covered Recipient Entity
University of Louisville Research Foundation Inc
A phase 2, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of 400 mg twice a day oral ladarixin in patients with new-onset type 1 diabetes and preserved cell function at baseline. NB THIS STUDY TITLE IS THE NEW STUDY TITLE; THE STUDY IS UNDERGOING PROTOCOL AMENDMENT SUBMISSIONS AND HAS CHANGED ITS STUDY PHASE AND STUDY TITLE. No dispute reported 06/30/2026 1248399028
Principal investigator 1 Dompe Farmaceutici S.p.A. $1,030.00 02/18/2025 Non-covered Recipient Entity
University of Louisville Research Foundation Inc
A phase 2, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of 400 mg twice a day oral ladarixin in patients with new-onset type 1 diabetes and preserved cell function at baseline. NB THIS STUDY TITLE IS THE NEW STUDY TITLE; THE STUDY IS UNDERGOING PROTOCOL AMENDMENT SUBMISSIONS AND HAS CHANGED ITS STUDY PHASE AND STUDY TITLE. No dispute reported 06/30/2026 1248399030